TL;DR
Canada’s drug regulatory agency has approved public reimbursement for Leqembi (lecanemab) to treat early Alzheimer’s disease. This decision follows a final positive recommendation, potentially expanding access to the drug nationwide.
Canada’s drug regulatory agency has issued a final positive recommendation supporting the public reimbursement of Leqembi (lecanemab) for patients with early Alzheimer’s disease. This decision marks a significant step toward increasing access to the drug across Canada, potentially impacting thousands of patients and their families. The move follows extensive review and is expected to influence provincial drug coverage policies nationwide.
The Canadian Agency for Drugs and Technologies in Health (CADTH) announced its final recommendation on March 2026, endorsing the public reimbursement of Leqembi for early Alzheimer’s disease. This recommendation is based on a comprehensive review of clinical data demonstrating the drug’s efficacy in slowing disease progression. The decision is expected to lead to coverage decisions by provincial health authorities, making Leqembi more accessible to eligible patients.
Leqembi, developed by Eisai and Biogen, received earlier approval from Health Canada in late 2025. The agencies’ final recommendation now signals a shift toward broader public access, aligning with ongoing efforts to address the growing burden of Alzheimer’s disease in Canada. The drug is intended for use in patients with mild cognitive impairment or early-stage Alzheimer’s, where it has shown potential to delay cognitive decline.
Officials from CADTH stated that the recommendation was made after evaluating safety, effectiveness, and cost-effectiveness data. The decision is expected to influence provincial drug formularies and reimbursement policies, although specific timelines for coverage expansion remain to be confirmed. The move has been welcomed by patient advocacy groups and healthcare providers eager to improve treatment options for early Alzheimer’s patients.
Implications for Alzheimer’s Treatment Access in Canada
This decision is a major development in Canadian healthcare policy, as it signals a commitment to funding innovative treatments for Alzheimer’s disease. Public reimbursement could significantly reduce financial barriers for patients, allowing earlier intervention and potentially improving quality of life. It also sets a precedent for future coverage of disease-modifying therapies in neurodegenerative conditions, which could influence policy debates and funding priorities across Canada.
Experts suggest that wider access to Leqembi might lead to earlier diagnosis and treatment, potentially easing the long-term burden on healthcare systems. However, questions remain about the extent of coverage, eligibility criteria, and the impact on provincial budgets, which will be clarified in subsequent policy decisions.
Leqembi (Lecanemab) for early Alzheimer’s treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Background on Leqembi and Alzheimer’s Policy Developments
Leqembi (lecanemab) is a monoclonal antibody designed to target amyloid plaques in the brain, a hallmark of Alzheimer’s disease. It received accelerated approval from Health Canada in late 2025 after clinical trials indicated it could slow cognitive decline in early-stage patients. The drug’s approval followed similar approvals in other jurisdictions, such as the U.S., where it has been part of ongoing discussions about the cost and accessibility of disease-modifying therapies.
Prior to this recommendation, access to Leqembi in Canada was limited, often restricted to clinical trials or private insurance plans, making it inaccessible to many patients. The move toward public reimbursement reflects a broader policy shift aimed at integrating innovative treatments into publicly funded healthcare, especially as Alzheimer’s prevalence rises with Canada’s aging population.
The decision by CADTH is part of a series of recent policy discussions about funding high-cost drugs that demonstrate significant clinical benefit, amid ongoing debates about drug pricing and health system sustainability.
Remaining Questions About Coverage and Implementation
While the final recommendation is confirmed, details about the timeline for provincial reimbursement decisions are still emerging. It is also unclear how broadly the drug will be covered, what eligibility criteria will be set, and how much patients will need to contribute out-of-pocket. Additionally, the long-term effects on healthcare budgets and system capacity remain to be assessed.
Experts warn that logistical and administrative hurdles could delay full implementation, and further guidance from provincial authorities is expected in the coming months.
Next Steps in Policy Adoption and Patient Access
Following the CADTH recommendation, provincial health authorities are expected to review and decide on coverage policies for Leqembi. This process could take several months, during which negotiations on pricing and eligibility will likely occur. Meanwhile, healthcare providers and patient groups are preparing to facilitate access once coverage is confirmed.
Monitoring of the drug’s real-world effectiveness and ongoing safety data will continue, informing future policy adjustments. Researchers and policymakers are also watching for developments in other neurodegenerative therapies that could influence coverage decisions further.
Key Questions
What is Leqembi and how does it work?
Leqembi (lecanemab) is a monoclonal antibody designed to target amyloid plaques in the brain, which are associated with Alzheimer’s disease. It aims to slow cognitive decline in early-stage patients by reducing these plaques.
When will Leqembi be covered publicly in Canada?
The final recommendation supports public reimbursement, but specific timelines for coverage decisions by provincial authorities are still being determined. Expect several months before widespread access is implemented.
Will all patients with early Alzheimer’s qualify for Leqembi?
Eligibility criteria are yet to be finalized, but coverage is expected to target patients with mild cognitive impairment or early-stage Alzheimer’s, based on clinical trial data and regulatory approvals.
How much will patients need to pay out-of-pocket?
Details on co-payments or patient contributions are still unclear. These will depend on provincial policies and reimbursement frameworks established after the coverage decisions.
What are the long-term implications of this decision?
The move could set a precedent for funding other costly neurodegenerative therapies, but questions about healthcare system capacity and budget impact remain open for future assessment.
Source: primary
